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Dear editor
Acute exacerbations of COPD (AECOPD) are markers of disease progression and 
severity, and frequently are used as an outcome variable in interventional studies.1 
AECOPD results in increased severity of symptoms and induces disease progres-
sion with accelerated decline in lung function and decreased quality of life. The 
risk of morbidity and mortality is also significantly increased. Most AECOPD 
(~85%) have an infectious etiology, induced by bacteria and viruses, often rhino-
virus (~50%).1
The paper by Johnston et al2 again emphasized the importance of the common 
cold and rhinoviruses in AECOPD. They found that cold-like symptoms are a reliable 
predictor of exacerbations in patients with COPD, occurring in over 80%, although 
actual viral detection occurred in less than half of these. Notably, the group with virus 
positivity exhibited more severe symptoms than other groups. They emphasized the 
need to better understand the relationship between rhinovirus and COPD.
Approximately 60% of human rhinoviruses serotypes adhere to the intercellular 
adhesion molecule-1 (ICAM-1). Recently, we showed that airway epithelial ICAM-1 
expression is upregulated throughout the respiratory tract in smokers, and is further 
increased in subjects with chronic airflow obstruction (including frank COPD), even 
when mild. Interestingly, ICAM-1 expression in goblet cells and submucosal glands 
in the airway wall was also markedly increased. Furthermore, cultured bronchial 
epithelial cells exposed to cigarette smoke extract exhibited significantly increased 
levels of ICAM-1, both at mRNA and protein levels.3 We suggest that such changes 
in pathogen adhesion sites may explain the increased vulnerability of COPD patients 
to virally induced exacerbations, which is otherwise essentially unexplained.
The issue of the potential importance of the upregulation of respiratory epithelial 
adhesion sites as a cause of certain specific bacteria and viruses being able to gain 
a serendipitous special niche in the airways in COPD needs much more attention, 
as it may open a potentially new nonantibiotic mode of prevention and treatment.4 
Haemophilus influenzae and Streptococcus pneumoniae are prominent in respira-
tory tract infection in smokers/COPD and are also associated with exacerbations. 
This may well relate to hyper-upregulation of their co-opted major airway epithelial 
adhesion molecule, the platelet-activating factor receptor. Platelet-activating factor 
receptor blockers were developed over 20 years ago for the anti-inflammatory treat-
ment of asthma, and proved safe but ineffective; they should now be trialed for this 
different indication.5
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Moreover, the data provided by Johnston et al2 suggest 
that an anti-ICAM-1 molecule given at an early stage of a 
common cold in frequent exacerbations of COPD could 
potentially have a prophylactic effect against these devastat-
ing and expensive events.
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